Abstract:Hutchinson–Gilford progeria is a premature ageing syndrome caused by progerin, a mutant form of lamin A (LA) that harbours a 50 amino acid (50AA) deletion and remains permanently farnesylated. By using a combination of genetic and pharmacological approaches, we demonstrate that the permanent farnesylation (and not the 50AA deletion) causes heterochromatin loss, DNA damage, proliferation defects and premature senescence; and regulates LA turnover. Importantly, early, but not late treatment with farnesyltransferase inhibitors prevent progerin‐induced defects. Hutchinson–Gilford Progeria syndrome (HGPS) is a severe premature ageing disorder caused by a 50 amino acid truncated (Δ50AA) and permanently farnesylated lamin A (LA) mutant called progerin. On a cellular level, progerin expression leads to heterochromatin loss, impaired nucleocytoplasmic transport, telomeric DNA damage and a permanent growth arrest called cellular senescence. Although the genetic basis for HGPS has been elucidated 20 years ago, the question whether the Δ50AA or the permanent farnesylation causes cellular defects has not been addressed. Moreover, we currently lack mechanistic insight into how the only FDA‐approved progeria drug Lonafarnib, a farnesyltransferase inhibitor (FTI), ameliorates HGPS phenotypes. By expressing a variety of LA mutants using a doxycycline‐inducible system, and in conjunction with FTI, we demonstrate that the permanent farnesylation, and not the Δ50AA, is solely responsible for progerin‐induced cellular defects, as well as its rapid accumulation and slow clearance. Importantly, FTI does not affect clearance of progerin post‐farnesylation and we demonstrate that early, but not late FTI treatment prevents HGPS phenotypes. Collectively, our study unravels the precise contributions of progerin's permanent farnesylation to its turnover and HGPS cellular phenotypes, and how FTI treatment ameliorates these. These findings are applicable to other diseases associated with permanently farnesylated proteins, such as adult‐onset autosomal dominant leukodystrophy.

Delayed localization of A-type lamins to the rupture sites in Hutchinson–Gilford progeria syndrome

Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover

Embryonic expression of the common progeroid lamin A splice mutation arrests postnatal skin development

Structural basis for the interaction between unfarnesylated progerin and the Ig-like domain of lamin A/C in premature aging disorders

Health care reform in the former Soviet Union: beyond the transition.

Phase Behavior and Dissociation Kinetics of Lamins in a Polymer Model of Progeria

The Accumulation of Progerin Underlies the Loss of Aortic Smooth Muscle Cells in Hutchinson-Gilford Progeria Syndrome

OmpA: A Flexible Clamp for Bacterial Cell Wall Attachment.

Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome

The Pathogenic Mechanisms and Therapeutic Strategies of Hutchinson-Gilford Progeria Syndrome

Cell autonomous and systemic factors in progeria development

Relationship Between Farnesylation of Prelamin A and Aging

Nuclear Abnormalities in LMNA p.(Glu2Lys) Variant Segregating with LMNA-Associated Cardiocutaneous Progeria Syndrome

Progerin impairs vascular smooth muscle cell growth via the DNA damage response pathway

Lamin A-Dependent Nuclear Defects in Human Aging

Molecular insights into the premature aging disease progeria

Cell aging caused by prelamin A mutation

Mice Harboring a R133L Heterozygous Mutation in LMNA Exhibited Ectopic Lipid Accumulation, Aging, and Mitochondrial Dysfunction in Adipose Tissue.

The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B

Progerin Can Induce DNA Damage in the Absence of Global Changes in Replication or Cell Proliferation

Arterial stiffness and cardiac dysfunction in Hutchinson-Gilford Progeria Syndrome corrected by inhibition of lysyl oxidase